Accelerate Diagnostics (AXDX) Stock Price
Accelerate Diagnostics Price
Over the last 19 years Accelerate Diagnostics grew revenue by 18.0% annually, reaching 11.70 M USD. For Accelerate Diagnostics, the net margin of -427.8% is up versus -700.5% a few years ago. The consensus 12-month price target for Accelerate Diagnostics is 2.04 USD, about 20,198.5% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Accelerate Diagnostics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Accelerate Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Accelerate Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Accelerate Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Accelerate Diagnostics Price |
|---|
Accelerate Diagnostics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Accelerate Diagnostics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | – | – | – | – | – | 4.00 | 5.00 | 9.00 | 11.00 | 11.00 | 12.00 | 12.00 | 11.00 | 12.00 | 22.00 |
| -50.00 | – | – | – | – | – | – | 25.00 | 80.00 | 22.22 | – | 9.09 | – | -8.33 | 9.09 | 83.33 |
| 100.00 | – | – | – | – | – | 75.00 | 40.00 | 44.44 | 36.36 | 18.18 | 25.00 | 16.67 | 18.18 | 18.18 | 18.18 |
| 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 4.00 | 4.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.18 | 4.00 |
| – | -5.00 | -15.00 | -31.00 | -45.00 | -66.00 | -64.00 | -80.00 | -72.00 | -63.00 | -62.00 | -62.00 | -55.00 | -37.00 | -12.00 | -22.00 |
| – | – | – | – | – | – | -1,600.00 | -1,600.00 | -800.00 | -572.73 | -563.64 | -516.67 | -458.33 | -336.36 | -100.00 | -100.00 |
| – | -5.00 | -15.00 | -30.00 | -45.00 | -66.00 | -62.00 | -88.00 | -84.00 | -78.00 | -77.00 | -62.00 | -61.00 | -50.00 | -46.00 | -8.00 |
| – | – | 200.00 | 100.00 | 50.00 | 46.67 | -6.06 | 41.94 | -4.55 | -7.14 | -1.28 | -19.48 | -1.61 | -18.03 | -8.00 | -82.61 |
| 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Accelerate Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Accelerate Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Accelerate Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Accelerate Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Accelerate Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Accelerate Diagnostics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Accelerate Diagnostics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Accelerate Diagnostics business model & stock analysis
Accelerate Diagnostics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Accelerate Diagnostics Segments
Accelerate Diagnostics Revenue by Segment (1/4)
Max
Details
Accelerate Diagnostics Revenue by Segment (2/4)
Max
Details
Accelerate Diagnostics Revenue by Segment (3/4)
3 Years
5 Years
Max
Details
Accelerate Diagnostics Revenue by Segment (4/4)
3 Years
5 Years
Max
Details
Accelerate Diagnostics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Accelerate Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio
Accelerate Diagnostics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Accelerate Diagnostics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Accelerate Diagnostics stock splits
Current Accelerate Diagnostics forecasts and price targets in September 2026
Analyst Price Targets 2026Accelerate Diagnostics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 4/1/2024 | Maintained | Hold | – | |
| 3/9/2022 | Downgrade | BuyHold | – | |
| 8/10/2020 | Maintained | Overweight | 56 | |
| 9/27/2019 | Downgrade | NeutralUnderweight | 53 | |
| 11/7/2018 | Downgrade | OverweightNeutral | 53 | |
| 12/19/2017 | Downgrade | BuyNeutral | 49 | |
| 12/13/2017 | Downgrade | BuyNeutral | 49 | |
| 8/9/2016 | Maintained | Overweight | 53 | |
| 8/25/2015 | Upgrade | NeutralBuy | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Accelerate Diagnostics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/19/2026 | -0.53USD | - | 3.16 MUSD | - | 2025 Q4 |
| 11/7/2024 | -0.48USD | - | 3.06 MUSD | - | 2024 Q3 |
| 5/9/2024 | -0.55USD | - | 4.22 MUSD | - | 2024 Q1 |
| 3/27/2024 | -0.63USD | - | 3.87 MUSD | - | 2023 Q4 |
| 11/13/2023 | -0.13USD | - | 4.62 MUSD | - | 2023 Q3 |
| 8/14/2023 | -0.15USD | - | 4.42 MUSD | - | 2023 Q2 |
| 5/15/2023 | -0.15USD | - | 4.21 MUSD | - | 2023 Q1 |
| 3/6/2023 | -0.17USD | - | 3.86 MUSD | - | 2022 Q4 |
| 11/14/2022 | -0.20USD | - | 3.81 MUSD | - | 2022 Q3 |
| 8/15/2022 | -0.29USD | - | 3.04 MUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Accelerate Diagnostics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Accelerate Diagnostics shareholder structure
| % | Name |
|---|---|
1.39576% | |
0.00382% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% |
Accelerate Diagnostics Beneficial Ownership Filings (SEC 13D/G)
Accelerate Diagnostics Executives and Management Board
13 members · avg. age 62 · 23 % women
Mr. John Phillips (59)
President, Chief Executive Officer, Director · since 2019
1.29 M USD
Management
Dr. Lawrence Mertz (62)
Chief Technology Officer
Mr. David Patience (39)
Chief Financial Officer
Board of Directors
Ms. Jennifer Regan (63)
Independent Director
Mr. Hany Massarany (63)
Independent Chairman of the Board
Mr. Mark Black (56)
Independent Director
Mr. Wayne Burris (70)
Independent Director
Ms. Louise Francesconi (72)
Independent Director
Ms. Marran Ogilvie (56)
Independent Director
Frequently asked questions about Accelerate Diagnostics
Analysts currently set an average price target of 2.04 USD for the Accelerate Diagnostics stock (median: 2.04 USD), implying +20,198.5 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Accelerate Diagnostics stock: 6 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Accelerate Diagnostics share trades at 0.01 EUR (0.01 USD).
The Accelerate Diagnostics share (AXDX) is listed on 5 stock exchanges, including: NASDAQ (AXDX), Frankfurt (1A8.F), Düsseldorf (1A8.DU), London (0H8E.L), SIX (Zürich) (1A8.SW).
No history available for Accelerate Diagnostics.
The expected revenue of Accelerate Diagnostics is 22.40 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Accelerate Diagnostics is -8.39 M USD. The net profit reflects the company's profitability after deducting all expenses.
The P/E ratio cannot be calculated for Accelerate Diagnostics at the moment.
The P/S cannot be calculated for Accelerate Diagnostics currently.
The Eulerpool Quality Score for Accelerate Diagnostics is 3/10.
The ISIN of Accelerate Diagnostics is US00430H2013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Accelerate Diagnostics is A1KA68. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Accelerate Diagnostics is AXDX. The ticker symbol is used to trade Accelerate Diagnostics shares on the stock exchange.
Accelerate Diagnostics paid dividends every year for the past 0 years.
Accelerate Diagnostics is assigned to the 'Health' sector.
The dividends of Accelerate Diagnostics are distributed in USD.
Accelerate Diagnostics stock
Accelerate Diagnostics Peer Group
Accelerate Diagnostics Ticker
All fundamentals and in-depth analysis of Accelerate Diagnostics
Our stock analysis for Accelerate Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Accelerate Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.